aTIGIT-IL15 Fusion Antibody
Oncology
Pre-clinicalActive
Key Facts
About MediMabBio
MediMabBio is a private, pre-clinical stage biotech pioneering precision immuno-oncology and autoimmune therapies through a rational protein design platform. The company, co-led by founders with deep expertise from Oxford, KAIST, and Samsung, focuses on engineering novel monoclonal antibodies and cytokine-antibody fusion proteins to overcome limitations of current immunotherapies. With a recent Series B funding of KRW 25.6 billion (approx. $18-20M), a growing pipeline, and a collaborative open-innovation business model, MediMabBio is positioning itself as a global player in next-generation biologics. Its research is supported by partnerships with academic institutions and industry players like Celltrion and Charles River.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |